1. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Issue 10191 (29th June 2019) Authors: Earl, Helena M; Hiller, Louise; Vallier, Anne-Laure; Loi, Shrushma; McAdam, Karen; Hughes-Davies, Luke; Harnett, Adrian N; Ah-See, Mei-Lin; Simcock, Richard; Rea, Daniel; Raj, Sanjay; Woodings, Pamela; Harries, Mark; Howe, Donna; Raynes, Kerry; Higgins, Helen B; Wilcox, Maggie; Plummer, Chris; Ma... Journal: Lancet Issue: Volume 393:Issue 10191(2019) Page Start: 2599 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Issue 10191 (29th June 2019) Authors: Earl, Helena M; Hiller, Louise; Vallier, Anne-Laure; Loi, Shrushma; McAdam, Karen; Hughes-Davies, Luke; Harnett, Adrian N; Ah-See, Mei-Lin; Simcock, Richard; Rea, Daniel; Raj, Sanjay; Woodings, Pamela; Harries, Mark; Howe, Donna; Raynes, Kerry; Higgins, Helen B; Wilcox, Maggie; Plummer, Chris; Ma... Journal: Lancet Issue: Volume 393:Issue 10191(2019) Page Start: 2599 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Docetaxel and its potential in the treatment of refractory esophagogastric adenocarcinoma. (July 2015) Authors: Ford, Hugo; Gounaris, Ioannis Journal: Therapeutic advances in gastroenterology Issue: Volume 8:Number 4(2015:Jul.) Page Start: 189 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial. Issue 6 (June 2015) Authors: Earl, Helena M; Hiller, Louise; Dunn, Janet A; Blenkinsop, Clare; Grybowicz, Louise; Vallier, Anne-Laure; Abraham, Jean; Thomas, Jeremy; Provenzano, Elena; Hughes-Davies, Luke; Gounaris, Ioannis; McAdam, Karen; Chan, Stephen; Ahmad, Rizvana; Hickish, Tamas; Houston, Stephen; Rea, Daniel; Bartlett... Journal: Lancet oncology Issue: Volume 16:Issue 6(2015:Jun.) Page Start: 656 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer. Issue 6 (July 2015) Authors: Sayal, Karen; Gounaris, Ioannis; Basu, Bristi; Freeman, Sue; Moyle, Penny; Hosking, Karen; Iddawela, Mahesh; Jimenez-Linan, Mercedes; Abraham, Jean; Brenton, James; Hatcher, Helen; Earl, Helena; Parkinson, Christine Journal: International journal of gynecological cancer Issue: Volume 25:Issue 6(2015:Jul.) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study. Issue 6 (1st July 2015) Authors: Sayal, Karen; Gounaris, Ioannis; Basu, Bristi; Freeman, Sue; Moyle, Penny; Hosking, Karen; Iddawela, Mahesh; Jimenez-Linan, Mercedes; Abraham, Jean; Brenton, James; Hatcher, Helen; Earl, Helena; Parkinson, Christine Journal: International journal of gynecological cancer Issue: Volume 25:Issue 6(2015:Jul.) Page Start: 977 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Intensive cisplatin/oral etoposide for epithelial ovarian cancer: the Cambridge Gynae-Oncology Centre experience. Issue 3 (March 2016) Authors: Gounaris, Ioannis; Iddawela, Mahesh; Parkinson, Christine; Pratt, Jennie; Hatcher, Helen; Basu, Bristi; Tan, Li Tee; Brenton, James D.; Earl, Helena M. Journal: Anti-cancer drugs Issue: Volume 27:Issue 3(2016) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Molecular pathogenesis of ovarian clear cell carcinoma. (May 2015) Authors: Gounaris, Ioannis; Brenton, James D Journal: Future oncology Issue: Volume 11:Number 9(2015) Page Start: 1389 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Practical implementation of the partial ordering continual reassessment method in a Phase I combination‐schedule dose‐finding trial. (25th November 2022) Authors: Mozgunov, Pavel; Jaki, Thomas; Gounaris, Ioannis; Goddemeier, Thomas; Victor, Anja; Grinberg, Marianna Journal: Statistics in medicine Issue: Volume 41:Number 30(2022) Page Start: 5789 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Ribociclib, a CDK 4/6 inhibitor, plus endocrine therapy in Asian women with advanced breast cancer. Issue 9 (28th July 2020) Authors: Yap, Yoon‐Sim; Chiu, Joanne; Ito, Yoshinori; Ishikawa, Takashi; Aruga, Tomoyuki; Kim, Seung Jin; Toyama, Tatsuya; Saeki, Toshiaki; Saito, Mitsue; Gounaris, Ioannis; Su, Fei; Ji, Yan; Han, Yu; Gazdoiu, Mihaela; Masuda, Norikazu Journal: Cancer science Issue: Volume 111:Issue 9(2020) Page Start: 3313 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗